drugset / Trial / NCT02099604
Efficacy and Safety of the Combination Vitamin D With Standard of Care in Egyptian Patients With Untreated Chronic Hepatitis C
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to show the superiority of a 4 weeks lead-in phase of Vitamin D followed by a 48 weeks combination of Vitamin D with PEG-IFN plus RBV in comparison with standard PEG-IFN + RBV in untreated Egyptian patients with chronic hepatitis C, on the sustained virological response (SVR) at 3 months after end of treatment (week 60).
Timeline
- Start
- 2014-04
- Primary completion
- 2014-04
- Completion
- 2014-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Vitamin D | Other / unclassified | 28000 iu | — |
| Background | Peginterferon alfa-2b | Protein / enzyme biologic | — | — |
| Background | Ribavirin | Small molecule | — | — |